Explore more publications!
Everything Worth Reading
Got News to Share?

Press Releases

Psychological Thriller Explores the Terrifying Power of Manipulation, Denial, and Family Loyalty
Feb. 4, 2026

Psychological Thriller Explores the Terrifying Power of Manipulation, Denial, and Family Loyalty

Neutral EIN Presswire
Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
Feb. 10, 2026

Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Indeterminate GlobeNewswire, Inc.
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Feb. 12, 2026

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Indeterminate GlobeNewswire, Inc.
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
Feb. 13, 2026

Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025

Indeterminate GlobeNewswire, Inc.
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
Feb. 10, 2026

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

Indeterminate GlobeNewswire, Inc.
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
Feb. 10, 2026

Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™

Indeterminate GlobeNewswire, Inc.
Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Feb. 10, 2026

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Indeterminate GlobeNewswire, Inc.
BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease
Feb. 10, 2026

BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease

Indeterminate GlobeNewswire, Inc.
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
Feb. 13, 2026

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

Indeterminate GlobeNewswire, Inc.
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
Feb. 12, 2026

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Indeterminate GlobeNewswire, Inc.
ECB and ESRB issue joint report analysing financial stability risks from linkages between banks and the non-bank financial intermediation sector
Feb. 12, 2026

ECB and ESRB issue joint report analysing financial stability risks from linkages between banks and the non-bank financial intermediation sector

Gov't Institution ECB - European Central Bank
Owner: European Union

ECB - European Central Bank

Gov't Institution
Owned By European Union (Central Banks of Member States)
Year Founded 1998
Website www.ecb.europa.eu
Domain Registration Year Indeterminate
Access Type open
Publication Location Germany, Frankfurt am Main

We welcome your feedback!
If you have comments or corrections, let us know.

From $54B to $85B: A Promising Decade for North America IVD
Feb. 12, 2026

From $54B to $85B: A Promising Decade for North America IVD

Indeterminate GlobeNewswire, Inc.
Agomab Announces Closing of Initial Public Offering
Feb. 9, 2026

Agomab Announces Closing of Initial Public Offering

Indeterminate GlobeNewswire, Inc.
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
Feb. 12, 2026

Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance

Indeterminate GlobeNewswire, Inc.
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
Feb. 12, 2026

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

Indeterminate GlobeNewswire, Inc.
OKYO Pharma Announces Public Offering of Ordinary Shares
Feb. 12, 2026

OKYO Pharma Announces Public Offering of Ordinary Shares

Indeterminate GlobeNewswire, Inc.
Esketamine treatments for severe depression
Feb. 9, 2026

Esketamine treatments for severe depression

Gov't Institution U.S. Department of Veterans Affairs
Owner: American Government

U.S. Department of Veterans Affairs

Gov't Institution
Owned By American Government
Year Founded 1989
Website https://www.va.gov/
Domain Registration Year Indeterminate
Access Type open
Publication Location United States, District of Columbia, Washington
Owner Country United States

We welcome your feedback!
If you have comments or corrections, let us know.

New Romantic Thriller 'Your Story Told by Another' Explores the Depths of the Soul Amidst International Intrigue
Feb. 5, 2026

New Romantic Thriller 'Your Story Told by Another' Explores the Depths of the Soul Amidst International Intrigue

Neutral EIN Presswire
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
Feb. 12, 2026

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

Indeterminate GlobeNewswire, Inc.
'L. Ron Hubbard Presents Writers of the Future Volume 42' Cover Revealed
Feb. 2, 2026

'L. Ron Hubbard Presents Writers of the Future Volume 42' Cover Revealed

Neutral EIN Presswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions